FR2401159B1 - - Google Patents

Info

Publication number
FR2401159B1
FR2401159B1 FR7815398A FR7815398A FR2401159B1 FR 2401159 B1 FR2401159 B1 FR 2401159B1 FR 7815398 A FR7815398 A FR 7815398A FR 7815398 A FR7815398 A FR 7815398A FR 2401159 B1 FR2401159 B1 FR 2401159B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7815398A
Other versions
FR2401159A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Co
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of FR2401159A1 publication Critical patent/FR2401159A1/fr
Application granted granted Critical
Publication of FR2401159B1 publication Critical patent/FR2401159B1/fr
Granted legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40Acylated substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
FR7815398A 1977-05-25 1978-05-24 Derives de 3-(1h-tetrazol-5-yl)-4h-pyrido(1,2-a)pyrimidine-4-one, leur procede de preparation et leur activite therapeutique Granted FR2401159A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/800,264 US4122274A (en) 1977-05-25 1977-05-25 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones

Publications (2)

Publication Number Publication Date
FR2401159A1 FR2401159A1 (fr) 1979-03-23
FR2401159B1 true FR2401159B1 (fr) 1983-05-20

Family

ID=25177928

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7815398A Granted FR2401159A1 (fr) 1977-05-25 1978-05-24 Derives de 3-(1h-tetrazol-5-yl)-4h-pyrido(1,2-a)pyrimidine-4-one, leur procede de preparation et leur activite therapeutique

Country Status (26)

Country Link
US (1) US4122274A (fr)
JP (1) JPS6050197B2 (fr)
AT (1) AT365187B (fr)
AU (1) AU521211B2 (fr)
BE (1) BE867295A (fr)
CA (1) CA1098520A (fr)
CH (1) CH642656A5 (fr)
CY (1) CY1218A (fr)
DE (1) DE2822544A1 (fr)
DK (1) DK160279C (fr)
FI (1) FI64594C (fr)
FR (1) FR2401159A1 (fr)
GB (1) GB1596476A (fr)
GR (1) GR71887B (fr)
HK (1) HK25884A (fr)
IE (1) IE46849B1 (fr)
IT (1) IT1105040B (fr)
KE (1) KE3357A (fr)
LU (1) LU79694A1 (fr)
MY (1) MY8500305A (fr)
NL (1) NL190702C (fr)
NO (1) NO150361C (fr)
SE (1) SE437830B (fr)
SG (1) SG73383G (fr)
YU (2) YU42163B (fr)
ZA (1) ZA782816B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU173438B (hu) * 1975-11-27 1979-05-28 Chinoin Gyogyszer Es Vegyeszet Sposob poluchenija novykh proizvodnykh 4-okso-1,6,7,8-/tetragidro-4h-pirido/1,2/pirimidina s zaderzhivajuhhejj vozgoranie aktivnot'ju i protivosvertivajuhhem effektom
US4495189A (en) * 1975-11-27 1985-01-22 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. Condensed pyrimidines
HU180439B (en) * 1977-12-29 1983-03-28 Chinoin Gyogyszer Es Vegyeszet Process for producing 9-amino-pyrido-square bracket-1,2-a-square bracket closed-pyrimidine derivatives
US4192944A (en) * 1978-04-03 1980-03-11 Bristol-Myers Company Optionally substituted 4-oxo-4H-pyrido[1,2-a]pyrimidine-3-N-(1H-tetrazol-4-yl)carboxamides and their use as antiallergy agents
US4491587A (en) * 1978-05-05 1985-01-01 Mead Johnson & Company Tetrazole derivatives
US4223031A (en) * 1978-05-05 1980-09-16 Mead Johnson & Company Azolopyrimidinones
US4282360A (en) * 1979-10-12 1981-08-04 Hoffmann-La Roche Inc. 7-Methylthio or methylsulfinyl-5-oxo-5H-thiazolo[2,3-b]quinazoline-2-carboxylic acid
US4419357A (en) * 1982-01-18 1983-12-06 The Dow Chemical Company 3-(1H-Tetrazol-5-yl)-4(3H)-quinazolinones
US4507477A (en) * 1982-09-09 1985-03-26 Riker Laboratories, Inc. Process for tetrazolyl-pyrimidinone derivatives
US4474953A (en) * 1982-09-09 1984-10-02 Riker Laboratories, Inc. Process and intermediates for the preparation of 3(1H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-ones
US4476130A (en) * 1982-09-09 1984-10-09 Riker Laboratories, Inc. 3-(1H-Tetrazol-5-yl)-4H-pyrimido[2,1-b]benzoxazol-4-one compounds exhibiting anti-allergic activity
US4457932A (en) * 1983-07-22 1984-07-03 Bristol-Myers Company Anti-ulcer agents
CA1283411C (fr) * 1985-09-25 1991-04-23 Masami Doteuchi Derives 9-(groupe thio substitue)-4h-pyrido(1,2a) pyrimidin-4-one
JPS63183581A (ja) * 1985-10-03 1988-07-28 Tokyo Tanabe Co Ltd ピリド〔1,2−a〕ピリミジン誘導体、その製造法及びそれを有効成分とするアレルギ−疾患治療薬
JPS62242682A (ja) * 1986-04-16 1987-10-23 Tokyo Tanabe Co Ltd 新規なピリド[1,2―a]ピリミジン誘導体及びその製造法
JP2504788B2 (ja) * 1987-11-10 1996-06-05 東京田辺製薬株式会社 9−メチル−3−(1H−テトラゾ―ル−5−イル)−4H−ピリド[1,2−a]ピリミジン−4−オンカリウム塩の水性製剤
US5034230A (en) * 1987-12-25 1991-07-23 Santen Pharmaceutical Co., Ltd. Anti-allergic ophthalmics
CA2010336C (fr) * 1989-02-27 1996-11-19 Atsunori Sano Procede de production d'un derive de pyrido [1,2-a] pyrimidine
HU209793B (en) * 1990-09-25 1994-11-28 Chinoin Gyogyszer Es Vegyeszet Process for the production of pyrido[1,2-a]pyrimidine-derivatives and pharmaceutical compositions containing the same
US5525605A (en) 1992-07-30 1996-06-11 Tokyo Tanabe Company Limited Remedy for inflammatory intestinal diseases
US5527802A (en) * 1992-10-01 1996-06-18 Bristol-Myers Squibb Company New uses of 3-tetrazolo -5,6,7,8- substituted-pyrido (1,2-a) pyrimidin-4-ones
JPH0892093A (ja) * 1994-11-10 1996-04-09 Tokyo Tanabe Co Ltd 9−メチル−3−(1H−テトラゾール−5−イル)−4H−ピリド[1,2−a]ピリミジン−4−オンの水性製剤
WO2002072580A1 (fr) * 2001-02-26 2002-09-19 Mitsubishi Pharma Corporation Preventifs et/ou remedes contres des maladies renales et l'insuffisance renale
ITMI20011764A1 (it) * 2001-08-10 2003-02-10 Dinamite Dipharma Spa Metodo per l'ottenimento del pemirolast ad elevata purezza
GB0316546D0 (en) * 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
JP2010513430A (ja) * 2006-12-18 2010-04-30 カルドズ・アーベー 炎症障害の治療において使用するための新たな併用
AU2007336077A1 (en) * 2006-12-20 2008-06-26 Cardoz Ab New combination for use in the treatment of inflammatory disorders
WO2009007679A2 (fr) * 2007-07-11 2009-01-15 Cardoz Ab Nouvelle association pour une utilisation dans le traitement de troubles inflammatoires
EP2175845A2 (fr) * 2007-07-11 2010-04-21 Cardoz AB Nouvelle combinaison pour une utilisation dans le traitement de troubles inflammatoires
WO2009007675A2 (fr) * 2007-07-11 2009-01-15 Cardoz Ab Nouvelle association pour une utilisation dans le traitement de troubles inflammatoires
WO2009125168A1 (fr) * 2008-04-07 2009-10-15 Cardoz Ab Nouvelle combinaison pour une utilisation dans le traitement de troubles inflammatoires
CA2765408A1 (fr) * 2009-06-16 2010-12-23 Cardoz Ab Formes d'hemihydrate cristallin de sel de sodium de pemirolast
USD661900S1 (en) 2010-02-22 2012-06-19 Bajer Design & Marketing, Inc. Collapsible structure
JP6092897B2 (ja) * 2012-02-10 2017-03-08 ピーティーシー セラピューティクス, インコーポレイテッド 脊髄性筋萎縮症を治療するための化合物
BR112014021531B1 (pt) 2012-03-01 2022-10-04 Ptc Therapeutics, Inc. Composto, composição farmacêutica e usos dos mesmos
EA028382B1 (ru) 2012-03-23 2017-11-30 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения спинальной мышечной атрофии
WO2015105657A1 (fr) 2013-12-19 2015-07-16 Ptc Therapeutics, Inc. Procédés pour moduler la quantité de transcrits d'arn
US20160243122A1 (en) 2014-10-23 2016-08-25 Rspr Pharma Ab Use of pemirolast in the treatment of acute asthma
WO2016102941A1 (fr) 2014-12-22 2016-06-30 Rspr Pharma Ab Nouvelle association pémirolast et montélukast
EP3298017B1 (fr) * 2015-05-20 2019-08-14 H. Hoffnabb-La Roche Ag Composés pour le traitement d'une amyotrophie spinale
US10668171B2 (en) 2015-05-30 2020-06-02 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
GB201518831D0 (en) 2015-10-23 2015-12-09 Rspr Pharma Ab New use
CN110946865B (zh) 2015-12-10 2024-01-26 Ptc医疗公司 用于治疗亨廷顿病的方法
GB201601138D0 (en) * 2016-01-21 2016-03-09 Rspr Pharma Ab New use
CA3043755A1 (fr) 2016-11-28 2018-05-31 Ptc Therapeutics, Inc. Procedes de modulation de l'epissage de l'arn
BR112019025740A2 (pt) 2017-06-05 2020-06-23 Ptc Therapeutics, Inc. Compostos para tratar a doença de huntington
CA3065547A1 (fr) 2017-06-14 2018-12-20 Ptc Therapeutics, Inc. Procedes de modification de l'epissage de l'arn
BR112019027719A2 (pt) 2017-06-28 2020-07-28 Ptc Therapeutics, Inc. métodos para tratar a doença de huntington
US11382918B2 (en) 2017-06-28 2022-07-12 Ptc Therapeutics, Inc. Methods for treating Huntington's Disease
SG11202009212WA (en) 2018-03-27 2020-10-29 Ptc Therapeutics Inc Compounds for treating huntington's disease
EP3814360A1 (fr) 2018-06-27 2021-05-05 PTC Therapeutics, Inc. Composés hétéroaryles pour le traitement de la maladie de huntington
EA202092896A1 (ru) 2018-06-27 2021-04-13 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Гетероциклические и гетероарильные соединения для лечения болезни гентингтона

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3072485A (en) * 1960-08-24 1963-01-08 Eastman Kodak Co Optically sensitized azido polymers for photomechanical resist compositions
CH538494A (de) * 1966-11-02 1973-06-30 Chinoin Gyogyszer Es Vegyeszet Verfahren zur Herstellung neuer Homopyrimidazol-Derivate
US3960847A (en) * 1972-04-17 1976-06-01 E. R. Squibb & Sons, Inc. 9-Substituted-4-oxopyrido(1,2-α)pyrimidine-3-carboxylic acids and derivatives thereof
US3929787A (en) * 1974-04-22 1975-12-30 Squibb & Sons Inc 6,7,8,9-Tetrahydro-pyrido(1,2-a)pyrimidin-4-ones
US3960863A (en) * 1974-06-25 1976-06-01 Sankyo Company Limited Pyrido[1,2-a]pyrimidinone derivatives
US4017625A (en) * 1975-08-01 1977-04-12 Pfizer Inc. Anti-allergic N-(5-tetrazolyl)-1-oxo-1H-6-alkoxypyrimido-[1,2-a]quinoline-2-carboxamides and intermediates therefor
US4012387A (en) * 1975-09-18 1977-03-15 Warner-Lambert Company Benzo-[g]pyrido[2,1-b]quinazolinones

Also Published As

Publication number Publication date
FR2401159A1 (fr) 1979-03-23
NO150361C (no) 1984-10-03
FI64594C (fi) 1983-12-12
AT365187B (de) 1981-12-28
IT7849523A0 (it) 1978-05-24
IT1105040B (it) 1985-10-28
GB1596476A (en) 1981-08-26
HK25884A (en) 1984-03-30
GR71887B (fr) 1983-08-04
SG73383G (en) 1984-08-03
YU42163B (en) 1988-06-30
SE7805954L (sv) 1978-11-26
NO150361B (no) 1984-06-25
NL190702B (nl) 1994-02-01
DE2822544A1 (de) 1978-12-07
DK160279B (da) 1991-02-18
SE437830B (sv) 1985-03-18
NO781786L (no) 1978-11-28
LU79694A1 (fr) 1979-02-02
MY8500305A (en) 1985-12-31
AU521211B2 (en) 1982-03-25
FI781614A (fi) 1978-11-26
DK228878A (da) 1978-11-26
BE867295A (fr) 1978-11-20
NL7805534A (nl) 1978-11-28
FI64594B (fi) 1983-08-31
AU3631978A (en) 1979-11-29
NL190702C (nl) 1994-07-01
CH642656A5 (de) 1984-04-30
CA1098520A (fr) 1981-03-31
JPS5436294A (en) 1979-03-16
DE2822544C2 (fr) 1988-10-27
IE46849B1 (en) 1983-10-05
JPS6050197B2 (ja) 1985-11-07
KE3357A (en) 1984-02-03
DK160279C (da) 1991-07-22
ATA373278A (de) 1981-05-15
US4122274A (en) 1978-10-24
YU233082A (en) 1988-08-31
YU44212B (en) 1990-04-30
CY1218A (en) 1984-04-06
YU123678A (en) 1983-02-28
IE781036L (en) 1978-11-25
ZA782816B (en) 1979-05-30

Similar Documents

Publication Publication Date Title
AU3353778A (fr)
AU495917B2 (fr)
AU71461S (fr)
BG25853A1 (fr)
BG25813A1 (fr)
BE851449A (fr)
BE865722A (fr)
BE866391A (fr)
BE868323A (fr)
BE870787A (fr)
BE871419A (fr)
BE871991A (fr)
BE872973A (fr)
BE873002A (fr)
BG23438A1 (fr)
BG23462A1 (fr)
BG24331A1 (fr)
BG25808A1 (fr)
BG25809A1 (fr)
BG25810A1 (fr)
BG25811A1 (fr)
BG25812A1 (fr)
BG25852A1 (fr)
BG25815A1 (fr)
BG25819A1 (fr)